Frontlight ResearchEarly access
TerminatedPhase 2
Pembro+Chemo in Brain Mets
Key facts
- Who runs it
- John L. Villano, MD, PhD
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 3 people enrolled
- Started
- 19 May 2022
- Ended
- 19 Dec 2023
- Type of study
- Interventional
- Treatments tested
- Pembrolizumab
- Nab paclitaxel
- Paclitaxel
- Pemetrexed
- Carboplatin
- Record updated
- 31 October 2025
- Why it stopped
- Slow Accrual
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Non-small cell lunch cancer (NSLC) with untreated asymptomatic brain metastases
- NSLC lacks oncogenic driver mutations
- Absence of new onset neurological symptoms
- Presence of fewer than ten intracranial lesions
- Each lesion measures three centimeters or less
- Life expectancy of greater than three months
- Adequate organ and marrow function
- Ability to understand and willingness to sign a written informed consent document
Who cannot take part
- Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration
- Receipt of a non-CNS minor surgical procedure (e.g. core biopsy or fine needle aspiration) within three days prior to registration
- Serious non-healing wound, ulcer or bone fracture
- History of allergic reactions attributed to monoclonal antibodies (mAb), compounds of similar chemical or biologic composition to Pembrolizumab
- Clinically significant cardiovascular disease
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Presence of oncogenic driver mutations
- Measurable lesion located within 10mm of the optic chiasm or optic nerve, or within the brainstem
- Known leptomeningeal involvement
- Midline shift
- Baseline inability to participate or complete neurocognitive testing
Where in United States
- University of Kentucky/Markey Cancer CenterLexington, United States
About the trial
What the trial wants to find out
The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
The group in the trial
- Pembrolizumab with standard of care chemotherapy treatmentTreatment being tested
Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
Treatment: Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, and Carboplatin
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
- Record updated
- 31 October 2025